In the News
By Media Staff | Friday, February 3, 2012
The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.
In the Lab
By Jim Stallard, MA, Writer/Editor | Wednesday, February 1, 2012
Memorial Sloan-Kettering researchers have performed the first large-scale genetic analysis of several pediatric cancers, identifying mutations and potential targets for therapies to treat the cancers.
By Eva Kiesler, PhD, Science Writer/Editor | Tuesday, January 31, 2012
Breast Surgical Service Chief Monica Morrow provides perspective on assessing the quality of surgical breast cancer treatment in an editorial in the February 1 issue of the Journal of the American Medical Association.
By Memorial Sloan-Kettering | Monday, January 30, 2012
While a diagnosis of cervical cancer once required a hysterectomy, a procedure called a radical trachelectomy eliminated Stephanie Luedke’s cancer and preserved her ability to bear a child.
By Memorial Sloan-Kettering | Wednesday, January 25, 2012
Our ovarian cancer nomogram is a personalized tool that can help you and your doctor make important treatment decisions after surgery.
By Esther Napolitano, BS, Science Writer/Editor | Monday, January 23, 2012
Research has shown that children who have experienced a sunburn at an early age are at almost double the risk for developing melanoma in adulthood. Now, a new study led by Memorial Sloan-Kettering epidemiologist Stephen Dusza finds that most children do not regularly use sunscreen.
In the Lab
By Julie Grisham, MS, Science Writer/Editor | Friday, January 20, 2012
Infections are a common cause of complications in cancer patients. Now a Memorial Sloan-Kettering research team finds that a commonly prescribed antibiotic could increase susceptibility to a bacterial infection.
By Memorial Sloan-Kettering | Thursday, January 19, 2012
When actor Michael Quinlan was diagnosed with prostate cancer, he came to Memorial Sloan-Kettering to learn about treatment options from our multidisciplinary team of experts. After undergoing robot-assisted laparoscopic surgery, he remains cancer-free.
By Memorial Sloan-Kettering | Tuesday, January 17, 2012
The Spine Tumor Center at Memorial Sloan-Kettering provides state-of-the-art diagnostic and treatment services for more than 1,500 people with primary or metastatic spine tumors each year.
In the Clinic
By Media Staff | Friday, January 13, 2012
Researchers at Memorial Sloan-Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.
By Memorial Sloan-Kettering | Thursday, January 12, 2012
Hundreds of high school students and teachers attended our sixth annual Major Trends in Modern Cancer Research seminar to learn about cutting-edge biomedical research and to engage with leading scientists.
By Julie Grisham, MS, Science Writer/Editor | Wednesday, December 28, 2011
Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.
By Craig Thompson, MD, President and CEO | Friday, December 23, 2011
Since the signing of the National Cancer Act in 1971, tremendous progress has been made in preventing and treating cancer—though challenges remain.
In the News
By Media Staff | Thursday, December 22, 2011
After signing up for the National Bone Marrow Registry “Be The Match,” a Montclair man was recently called to donate peripheral blood stem cells for a sick child. He was inspired to join the registry after an anonymous donor saved the life of his own son, who had received a bone marrow transplant.
By Memorial Sloan-Kettering | Wednesday, December 21, 2011
As a tribute to Memorial Sloan-Kettering Board member Josephine “Josie” Robertson, Memorial Sloan-Kettering has joined with The Robertson Foundation to undertake two high-profile initiatives — the Josie Robertson Surgery Center and the Josie Robertson Investigators Program — made possible by a $50 million commitment from The Robertson Foundation.